NCT00281606View on ClinicalTrials.gov

A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 14, 2006

Primary Completion Date

October 16, 2007

Study Completion Date

June 13, 2012

Conditions
HIV Infection
Interventions
DRUG

Different formulations of once-daily lopinavir/ritonavir

CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules

Trial Locations (5)

90033

USC, Los Angeles

90502

Harbor-UCLA Medical Center, Torrance

92103

UCSD, San Diego

92668

UCI, Irvine

95128

Santa Clara Valley Medical Center, San Jose

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University of California, San Diego

OTHER